|
8 Companies |
|
9 Products |
|
9 Products |
|
6 Mechanisms of Action |
|
0 Trials |
|
40 News |
|
- || Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion
Trial completion: Intravenous Immunoglobulin (IVIG) in Lung Transplantation (clinicaltrials.gov) - Mar 5, 2019
P2, N=11, Completed, Sponsor: Columbia University
Active, not recruiting --> Completed
- || Zostavax (zoster vaccine live) / Merck (MSD)
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older (clinicaltrials.gov) - Jun 1, 2018
P=N/A, N=2, Terminated, Sponsor: University of South Florida
Active, not recruiting --> Completed N=50 --> 2 | Trial completion date: Dec 2019 --> Dec 2017 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Dec 2017; PI has terminated the study at this time.
- lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Jan 16, 2018
P2, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
N=50 --> 2 | Trial completion date: Dec 2019 --> Dec 2017 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Dec 2017; PI has terminated the study at this time. Trial primary completion date: Nov 2018 --> Feb 2017
- | Subgam (human normal immunoglobulin) / Bio Products Laboratory (BPL)
Trial completion: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Aug 7, 2017
P3, N=38, Completed, Sponsor: Bio Products Laboratory
Trial primary completion date: Nov 2018 --> Feb 2017 Active, not recruiting --> Completed
- lenalidomide / Generic mfg.
Trial termination: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 24, 2017
P2, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Slow Accrual
- Subgam (human normal immunoglobulin) / Bio Products Laboratory (BPL)
Enrollment closed, Enrollment change: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Jan 4, 2017
P3, N=38, Active, not recruiting, Sponsor: Bio Products Laboratory
Active, not recruiting --> Terminated; Slow Accrual Recruiting --> Active, not recruiting | N=50 --> 38
- Subgam (human normal immunoglobulin) / Bio Products Laboratory (BPL)
Trial primary completion date: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Nov 29, 2016
P3, N=50, Recruiting, Sponsor: Bio Products Laboratory
Recruiting --> Active, not recruiting | N=50 --> 38 Trial primary completion date: Nov 2016 --> Jul 2017
- Subgam (human normal immunoglobulin) / Bio Products Laboratory (BPL)
Enrollment change: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Nov 15, 2016
P3, N=50, Recruiting, Sponsor: Bio Products Laboratory
Trial primary completion date: Nov 2016 --> Jul 2017 N=35 --> 50
- lenalidomide / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 11, 2016
P2, N=3, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=35 --> 50 Recruiting --> Active, not recruiting | N=35 --> 3 | Trial primary completion date: Nov 2017 --> Nov 2018
- | lenalidomide / Generic mfg.
Enrollment open: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 12, 2016
P2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=35 --> 3 | Trial primary completion date: Nov 2017 --> Nov 2018 Active, not recruiting --> Recruiting
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
Trial completion, Trial primary completion date: GMX07: Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases (clinicaltrials.gov) - May 12, 2016
P3, N=48, Completed, Sponsor: Bio Products Laboratory
Active, not recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2016
- | lenalidomide / Generic mfg.
Enrollment closed: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 6, 2016
P2, N=35, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2016 Recruiting --> Active, not recruiting
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
Trial primary completion date: GMX07: Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Jan 18, 2016
P3, N=48, Recruiting, Sponsor: Bio Products Laboratory
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2015 --> Jun 2016
- Trial completion, Enrollment change, Gene therapy: Gene Therapy ADA Deficiency (clinicaltrials.gov) - Sep 15, 2015
P1/2, N=8, Completed, Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust
Trial primary completion date: Sep 2015 --> Jun 2016 Recruiting --> Completed | N=10 --> 8
- Subgam (human normal immunoglobulin) / Bio Products Laboratory (BPL)
Enrollment open: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Aug 20, 2015
P3, N=35, Recruiting, Sponsor: Bio Products Laboratory
Recruiting --> Completed | N=10 --> 8 Not yet recruiting --> Recruiting
- Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion
Trial completion, Trial primary completion date: Intravenous Immunoglobulin for Early Prevention of Cardiopulmonary Bypass Induced Hypogammaglobulinemia in Infants and Neonates (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=50, Completed, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2015
- Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion
Trial primary completion date: Intravenous Immunoglobulin for Early Prevention of Cardiopulmonary Bypass Induced Hypogammaglobulinemia in Infants and Neonates (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=50, Recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jun 2015 Trial primary completion date: Mar 2015 --> Dec 2015
- Subgam (human normal immunoglobulin) / Bio Products Laboratory (BPL)
Trial initiation date, Trial primary completion date: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Jun 11, 2015
P3, N=35, Not yet recruiting, Sponsor: Bio Products Laboratory
Trial primary completion date: Mar 2015 --> Dec 2015 Initiation date: Jan 2015 --> Aug 2015 | Trial primary completion date: Jan 2016 --> Nov 2016
- Enrollment change, Viral vector: Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector (clinicaltrials.gov) - Apr 14, 2015
P1, N=1, Completed, Sponsor: National Human Genome Research Institute (NHGRI)
Initiation date: Jan 2015 --> Aug 2015 | Trial primary completion date: Jan 2016 --> Nov 2016 N=10 --> 1
- | lenalidomide / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Nov 25, 2014
P2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=10 --> 1 Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Nov 2014 | Trial primary completion date: Feb 2018 --> Nov 2017
- | lenalidomide / Generic mfg.
Trial initiation date, Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Nov 19, 2014
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Nov 2014 | Trial primary completion date: Feb 2018 --> Nov 2017 Initiation date: Nov 2014 --> Feb 2015 | Trial primary completion date: Nov 2017 --> Feb 2018
- | lenalidomide / Generic mfg.
Enrollment open: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Nov 7, 2014
P2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Nov 2014 --> Feb 2015 | Trial primary completion date: Nov 2017 --> Feb 2018 Withdrawn --> Recruiting
- lenalidomide / Generic mfg.
Enrollment change, Trial withdrawal: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 24, 2014
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Withdrawn --> Recruiting N=35 --> 0 | Not yet recruiting --> Withdrawn
- Trial completion, Trial primary completion date, Viral vector: Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector (clinicaltrials.gov) - Oct 10, 2014
P1, N=10, Completed, Sponsor: National Human Genome Research Institute (NHGRI)
N=35 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Dec 2013
- Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion
Trial initiation date: Intravenous Immunoglobulin for Early Prevention of Cardiopulmonary Bypass Induced Hypogammaglobulinemia in Infants and Neonates (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=50, Recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed | Trial primary completion date: Mar 2016 --> Dec 2013 Initiation date: Jan 2014 --> May 2014
- Gamunex (intravenous normal human immunoglobulin 10%) / Bayer, Grifols, Kedrion
Enrollment open: Intravenous Immunoglobulin for Early Prevention of Cardiopulmonary Bypass Induced Hypogammaglobulinemia in Infants and Neonates (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=50, Recruiting, Sponsor: University of Alabama at Birmingham
Initiation date: Jan 2014 --> May 2014 Not yet recruiting --> Recruiting
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
Trial completion: A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency (clinicaltrials.gov) - May 26, 2014
P4, N=25, Completed, Sponsor: Bio Products Laboratory
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 8, 2014
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Oct 2017
- | lenalidomide / Generic mfg.
Trial initiation date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 8, 2014
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2017 --> Oct 2017 Initiation date: Feb 2014 --> Oct 2014
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
Enrollment open: GMX07: Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Feb 20, 2014
P3, N=48, Recruiting, Sponsor: Bio Products Laboratory
Initiation date: Feb 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- Subgam (human normal immunoglobulin) / Bio Products Laboratory (BPL)
Trial suspension: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Jan 28, 2014
P3, N=35, Suspended, Sponsor: Bio Products Laboratory
Not yet recruiting --> Recruiting Not yet recruiting --> Suspended
- Subgam (human normal immunoglobulin) / Bio Products Laboratory (BPL)
Trial initiation date: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Jan 28, 2014
P3, N=35, Suspended, Sponsor: Bio Products Laboratory
Not yet recruiting --> Suspended Initiation date: Oct 2013 --> Jan 2015
- Subgam (human normal immunoglobulin) / Bio Products Laboratory (BPL)
Enrollment change: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Jan 28, 2014
P3, N=35, Suspended, Sponsor: Bio Products Laboratory
Initiation date: Oct 2013 --> Jan 2015 N=45 --> 35
- New P1 trial, Viral vector: Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector (clinicaltrials.gov) - Dec 26, 2013
P1, N=10, Recruiting, Sponsor: National Human Genome Research Institute (NHGRI)
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
New P3 trial: GMX07: Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Oct 14, 2013
P3, N=48, Recruiting, Sponsor: Bio Products Laboratory
- | lenalidomide / Generic mfg.
New P2 trial: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Aug 14, 2013
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Subgam (human normal immunoglobulin) / Bio Products Laboratory (BPL)
New P3 trial: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases (clinicaltrials.gov) - Jun 20, 2013
P3, N=35, Suspended, Sponsor: Bio Products Laboratory
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
Enrollment closed: A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency (clinicaltrials.gov) - Mar 21, 2013
P4, N=25, Active, not recruiting, Sponsor: Bio Products Laboratory
N=45 --> 35 Recruiting --> Active, not recruiting
- ||||| Enrollment change: Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) (clinicaltrials.gov) - Sep 26, 2012
P3, N=55, Completed, Sponsor: CSL Behring
Recruiting --> Active, not recruiting N=44 --> 55